The FASEB Journal · 2005 · 19 citations · 23 references
MedicineCardiologyImmunologyCardiac Nuclear MedicineCardiac TransplantationTransplant ImmunologyHeart TransplantationVascular RegenerationCell Proliferation KineticsGraft Failure DetectionGraft Vascular RemodelingLate Graft DysfunctionTracer ExperimentsTransplant Coronary Artery DiseaseTransplantationVascular Targeting
Graft arteriopathy (GA), characterized by diffuse concentric narrowing of coronary arteries, is the major cause of late graft failure in cardiac transplantation. alphavbeta3 Integrin is up-regulated in proliferating vascular cells and may constitute an appropriate target for imaging GA. We used a human/mouse chimeric model of GA, in which segments of human coronary artery were transplanted to severe combined immunodeficiency mice, followed by reconstitution with allogeneic human peripheral blood mononuclear cells (PBMC). This led to vascular remodeling characterized by neointima formation over a period of 4 wk. alphavbeta3 expression in the graft was minimal in animals without PBMC, considerably increased by 2 wk, and decreased toward baseline by 4 wk after PBMC reconstitution. Cell proliferation was maximal at 2 wk, correlating with peak alphavbeta3 expression. RP748, an 111In-labeled alphavbeta3 (active conformation)-targeted radiotracer was injected into groups of 5 recipients at 0, 2, and 4 wk after PBMC reconstitution. Relative uptakes, defined as autoradiographic intensity in the graft/native aortas closely tracked the proliferative process. Specificity of uptake was demonstrated using excess nonlabeled tracer. In conclusion, alphavbeta3 integrin is transiently up-regulated (and activated) in GA and may be targeted by RP748 for detection of the proliferative process in early GA.
23
Interferon-γ elicits arteriosclerosis in the absence of leukocytes
George Tellides, Denis A. Tereb, Nancy C. Kirkiles-Smith et al. · Nature · 2000 · 392 citations
Life Sciences, Immunology, Pathology +10
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
Roland Haubner, Hans‐Jürgen Wester, Ute Reuning et al. · PubMed · 1999 · 356 citations
Medicine, Oncology, Pharmacology +17